In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP to revise Part D drug guidelines

Executive Summary

U.S. Pharmacopeia's Model Guidelines Expert Committee will meet Nov. 1-2 to discuss revisions to the list of drug categories and classes to be used by Medicare Part D drug plans in developing formularies. The group will update the guidelines to account "for new Part D drugs and new therapeutic uses of Part D drugs." USP will submit draft revised guidelines and a final report to the Centers for Medicare & Medicaid Services by Jan. 30. The initial guidelines, issued in December 2004, were followed by about half of the prescription drug plans that submitted formularies to CMS (1"The Pink Sheet" Sept. 26, 2005, p. 17)...

You may also be interested in...



USP Formulary Guidelines Adopted By Half Of Medicare Drug Plans

About half of Medicare prescription drug plans submitted to CMS followed the formulary guidelines created by the U.S. Pharmacopeia

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS046503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel